The emerging therapeutic efficacy of ketamine and classical psychedelics for depression
has inspired tremendous interest in the underlying neurobiological mechanisms. We review …

A revamped interest in the study of hallucinogens has recently emerged, especially with
regard to their potential application in the treatment of psychiatric disorders. In the last …

Mounting evidence suggests safety and efficacy of psychedelic compounds as potential
novel therapeutics in psychiatry. Ketamine has been approved by the Food and Drug …

Our hominin ancestors inevitably encountered and likely ingested psychedelic mushrooms
throughout their evolutionary history. This assertion is supported by current understanding …

The discovery of ketamine as a rapid-acting antidepressant spurred significant research to
understand its underlying mechanisms of action and to identify other novel compounds that …

Background: Evidence suggests that serotonergic psychedelics (eg psilocybin), have rapid-
acting and long-lasting antidepressant effects after a single dose. However, the mechanism …

Background The glutamatergic modulator ketamine has created a blueprint for studying
novel pharmaceuticals in the field. Recent studies suggest that “classic” serotonergic …

Renewed interest in classic psychedelics as treatments for psychiatric disorders warrants a
deeper understanding of their neural mechanisms. Single, high doses of psychedelic drugs …

Rationale Classical psychedelics, including psilocybin and lysergic acid diethylamide (LSD),
are under investigation as potential therapeutic agents in psychiatry. Whereas most studies …

The profound changes in perception and cognition induced by psychedelic drugs are
thought to act on several levels, including increased glutamatergic activity, altered functional …